SOTHEMA's revenue for the
six
months ended in Dec. 2025 was MAD1,676 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was MAD3,226 Mil.
SOTHEMA's Revenue per Share for the
six
months ended in Dec. 2025 was MAD41.84.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was MAD84.88.
Warning Sign:
SOTHEMA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of SOTHEMA was 8.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -8.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, SOTHEMA's highest 3-Year average Revenue per Share Growth Rate was 71.90% per year. The lowest was -29.80% per year. And the median was 10.15% per year.
SOTHEMA (CAS:SOT) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
SOTHEMA Revenue Related Terms
SOTHEMA Revenue Historical Data
* Premium members only.
The historical data trend for SOTHEMA's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, SOTHEMA's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOTHEMA Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SOTHEMA's Revenue distribution charts can be found below:
* The bar in red indicates where SOTHEMA's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MAD3,226 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOTHEMA (CAS:SOT) has a Revenue of MAD3,226 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on SOTHEMA and its competitors.
Is SOTHEMA's Revenue too high?
SOTHEMA's current Revenue is MAD3,226 Mil. Overall, SOTHEMA has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's Revenue compare to LLY and JNJ?
SOTHEMA's Revenue of MAD3,226 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on SOTHEMA and its competitors. SOTHEMA's current Revenue is MAD3,226 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Modestly Overvalued. The stock's GF Value™ is MAD286.01, compared to a current price of MAD369.80 — trading 29.3% above its estimated fair value. The current Revenue is MAD3,226 Mil. SOTHEMA's overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current Revenue is MAD3,226 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOTHEMA (CAS:SOT) Overvalued in 2026?
Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued.
The current stock price of MAD369.80 is trading 29.3% above its estimated GF Value™ of MAD286.01.
GuruFocus considers SOTHEMA to be Modestly Overvalued.
Key valuation signals for CAS:SOT:
Revenue: MAD3,226 Mil
GF Value™: MAD286.01 vs. price of MAD369.80 (29.3% above fair value)
No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
73GF Score
Get the complete analysis for CAS:SOT
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:SOT has been successfully added to your 
